CN115244075A - 针对含有g12v突变的ras的hla ii类限制性t细胞受体 - Google Patents

针对含有g12v突变的ras的hla ii类限制性t细胞受体 Download PDF

Info

Publication number
CN115244075A
CN115244075A CN202180016761.4A CN202180016761A CN115244075A CN 115244075 A CN115244075 A CN 115244075A CN 202180016761 A CN202180016761 A CN 202180016761A CN 115244075 A CN115244075 A CN 115244075A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180016761.4A
Other languages
English (en)
Chinese (zh)
Inventor
诺姆·莱文
拉米·约瑟夫
比曼·C·帕里亚
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CN115244075A publication Critical patent/CN115244075A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
CN202180016761.4A 2020-02-26 2021-02-26 针对含有g12v突变的ras的hla ii类限制性t细胞受体 Pending CN115244075A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981856P 2020-02-26 2020-02-26
US62/981,856 2020-02-26
PCT/US2021/019775 WO2021173902A1 (en) 2020-02-26 2021-02-26 Hla class ii-restricted t cell receptors against ras with g12v mutation

Publications (1)

Publication Number Publication Date
CN115244075A true CN115244075A (zh) 2022-10-25

Family

ID=74885105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180016761.4A Pending CN115244075A (zh) 2020-02-26 2021-02-26 针对含有g12v突变的ras的hla ii类限制性t细胞受体

Country Status (12)

Country Link
US (1) US20230159614A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110804A1 (cg-RX-API-DMAC7.html)
JP (1) JP7742354B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220143939A (cg-RX-API-DMAC7.html)
CN (1) CN115244075A (cg-RX-API-DMAC7.html)
AU (1) AU2021225872A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169086A1 (cg-RX-API-DMAC7.html)
GB (1) GB2610069B (cg-RX-API-DMAC7.html)
MX (1) MX2022010157A (cg-RX-API-DMAC7.html)
TW (1) TWI900533B (cg-RX-API-DMAC7.html)
WO (1) WO2021173902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ras突然変異体エピトープペプチドおよびras突然変異体を認識するt細胞受容体
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108350059A (zh) * 2015-09-15 2018-07-31 美国卫生和人力服务部 识别hla-cw8限制性突变kras的t细胞受体
CN109790211A (zh) * 2016-08-02 2019-05-21 美国卫生和人力服务部 抗kras-g12d t细胞受体
CN111201237A (zh) * 2017-09-20 2020-05-26 美国卫生和人力服务部 针对突变的ras的hla ii类限制性t细胞受体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
US20210061876A1 (en) * 2017-12-29 2021-03-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
GB201804724D0 (en) * 2018-03-23 2018-05-09 Univ Oslo Hf Method of diagnosing cceliac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
JP2024507929A (ja) * 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108350059A (zh) * 2015-09-15 2018-07-31 美国卫生和人力服务部 识别hla-cw8限制性突变kras的t细胞受体
CN109790211A (zh) * 2016-08-02 2019-05-21 美国卫生和人力服务部 抗kras-g12d t细胞受体
CN111201237A (zh) * 2017-09-20 2020-05-26 美国卫生和人力服务部 针对突变的ras的hla ii类限制性t细胞受体

Also Published As

Publication number Publication date
TWI900533B (zh) 2025-10-11
MX2022010157A (es) 2022-10-18
US20230159614A1 (en) 2023-05-25
JP7742354B2 (ja) 2025-09-19
BR112022016661A2 (pt) 2022-10-11
GB2610069B (en) 2025-04-16
GB2610069A (en) 2023-02-22
KR20220143939A (ko) 2022-10-25
JP2023527613A (ja) 2023-06-30
TW202140537A (zh) 2021-11-01
WO2021173902A1 (en) 2021-09-02
EP4110804A1 (en) 2023-01-04
GB202212195D0 (en) 2022-10-05
AU2021225872A1 (en) 2022-09-15
CA3169086A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7620676B2 (ja) 突然変異rasに対するhlaクラスi拘束性t細胞受容体
TWI900528B (zh) 針對含有g12d突變之ras之hla第i類限制性t細胞受體
JP7735285B2 (ja) G12v突然変異rasに対するhlaクラスi拘束性t細胞受容体
JP7742354B2 (ja) G12v変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP2025114614A (ja) G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP2023544592A (ja) G13d変異を有するrasに対するhlaクラスii拘束性dq t細胞受容体
JP2023534241A (ja) G12d変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
RU2849866C1 (ru) T-клеточные рецепторы, рестриктированные по hla класса i, против ras с мутацией g12d
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination